Curis reports Q3 EPS ($1.70), consensus ( $1.88)

Reports Q3 revenue $2.9M vs. $2.8M last year. “We continue to make excellent progress across our clinical programs. We are especially excited about the recent R/R PCNSL data released in September which continue to demonstrate the activity of emavusertib in combination with ibrutinib in salvage-line patients and that the CR/CRu responses appear to be durable,” said CEO James Dentzer. “We are also excited to present additional clinical data in our TakeAim Leukemia study next month at ASH. We believe the positive momentum as we finish the year sets us up well for 2025.”